Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen

G. C. Kudva, M. Chandy, D. Dennison, A. Srivastava, V. Bhushan

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Sixty-two adults with acute lymphoblastic leukaemia (ALL) were treated with a modified BFM regimen. Forty-two (70%) achieved complete remission (CR). Twenty-two percent of all evaluable patients and 32.4 percent of complete responders are in continuous complete remission (CCR) at a median follow-up of 41 months (range 24-81 months). Long-term survival was better in T- ALL (47.1%) when compared to precursor-B ALL (4.8%) (P < 0.04).

Original languageEnglish
Pages (from-to)1-7
Number of pages7
JournalIndian Journal of Cancer
Volume31
Issue number1
Publication statusPublished - 1994

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Therapeutics
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Medicine(all)
  • Oncology

Cite this

Kudva, G. C., Chandy, M., Dennison, D., Srivastava, A., & Bhushan, V. (1994). Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen. Indian Journal of Cancer, 31(1), 1-7.

Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen. / Kudva, G. C.; Chandy, M.; Dennison, D.; Srivastava, A.; Bhushan, V.

In: Indian Journal of Cancer, Vol. 31, No. 1, 1994, p. 1-7.

Research output: Contribution to journalArticle

Kudva, GC, Chandy, M, Dennison, D, Srivastava, A & Bhushan, V 1994, 'Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen', Indian Journal of Cancer, vol. 31, no. 1, pp. 1-7.
Kudva, G. C. ; Chandy, M. ; Dennison, D. ; Srivastava, A. ; Bhushan, V. / Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen. In: Indian Journal of Cancer. 1994 ; Vol. 31, No. 1. pp. 1-7.
@article{48ff8ed4e694432fa0aa5401b86a8684,
title = "Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen",
abstract = "Sixty-two adults with acute lymphoblastic leukaemia (ALL) were treated with a modified BFM regimen. Forty-two (70{\%}) achieved complete remission (CR). Twenty-two percent of all evaluable patients and 32.4 percent of complete responders are in continuous complete remission (CCR) at a median follow-up of 41 months (range 24-81 months). Long-term survival was better in T- ALL (47.1{\%}) when compared to precursor-B ALL (4.8{\%}) (P < 0.04).",
author = "Kudva, {G. C.} and M. Chandy and D. Dennison and A. Srivastava and V. Bhushan",
year = "1994",
language = "English",
volume = "31",
pages = "1--7",
journal = "Indian Journal of Cancer",
issn = "0019-509X",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen

AU - Kudva, G. C.

AU - Chandy, M.

AU - Dennison, D.

AU - Srivastava, A.

AU - Bhushan, V.

PY - 1994

Y1 - 1994

N2 - Sixty-two adults with acute lymphoblastic leukaemia (ALL) were treated with a modified BFM regimen. Forty-two (70%) achieved complete remission (CR). Twenty-two percent of all evaluable patients and 32.4 percent of complete responders are in continuous complete remission (CCR) at a median follow-up of 41 months (range 24-81 months). Long-term survival was better in T- ALL (47.1%) when compared to precursor-B ALL (4.8%) (P < 0.04).

AB - Sixty-two adults with acute lymphoblastic leukaemia (ALL) were treated with a modified BFM regimen. Forty-two (70%) achieved complete remission (CR). Twenty-two percent of all evaluable patients and 32.4 percent of complete responders are in continuous complete remission (CCR) at a median follow-up of 41 months (range 24-81 months). Long-term survival was better in T- ALL (47.1%) when compared to precursor-B ALL (4.8%) (P < 0.04).

UR - http://www.scopus.com/inward/record.url?scp=0028041607&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028041607&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 1

EP - 7

JO - Indian Journal of Cancer

JF - Indian Journal of Cancer

SN - 0019-509X

IS - 1

ER -